Okta can expect a new pool of buyers for its stock as a member of the S&P 500. Kenvue is being acquired and will therefore depart the index.
Why GKOS Stock surged +33.65% Today — RQD Quant Desk Flash
Glaukos Corporation (GKOS) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Why GKOS Stock surged +33.65% Today — RQD Quant Desk Flash
Glaukos Corporation (GKOS) surged +33.65% to $242.48 as options desks priced 72% call premium vs. 28% put protection around the $238 max-pain magnet. Solid 56% profit margin (-14% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 96% of its 52-week range ($80.91 – $248.75) with RSI-14 at 82.6 (OVERBOUGHT (>70)).
- ▸Whale Options Positioning: $3.3M in bullish call flow vs. $1.2M in put flow (Put/Call 0.38x, implied earnings swing ±7%).
- ▸Fundamental Anchor: Roarable C+ (Hold) backed by 55.7% gross margin and $0 annual free cash flow.
S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on Wednesday, November 4:
Stryker shares plunge 11.8% after Q3 earnings and sales miss estimates, prompting a 2026 outlook cut amid weak joint procedures and execution challenges.
Glaukos Corp. (NYSE:GKOS)—an ophthalmic medical technology and pharmaceutical company—soared to a new all-time high on Thursday amid positive catalysts, including strong earnings, a higher growth outlook, and bullish ana
Glaukos came into the Q3 2026 print with a hot chart and a premium story, and the stock just got even hotter. Shares jumped 33.65% in the first full session after results, a large move for a medical device specialist tha
US session market movers: NUBURU led gainers at 125.0% while GameStop's GME.W fell 48.11% among the biggest losers.
Glaukos’ two newer launches are carrying the company, and its 2027 target may be too low. Here’s what to watch.
US top gainers and losers for Oct. 29, 2026, ranked by percentage change, led by BURU's 117.0% gain and GME.W's 46.08% decline.
HC Wainwright & Co. analyst Yi Chen maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $195 to $248.
JP Morgan analyst Allen Gong maintains Glaukos (NYSE:GKOS) with a Overweight and raises the price target from $200 to $240.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live GKOS Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
GKOS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +32.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GKOS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GKOS. Explore sector supply chains on /butterfly.
GKOS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is GKOS stock moving today?
Why GKOS Stock surged +33.65% Today — RQD Quant Desk Flash. Solid 56% profit margin (-14% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.